Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

389
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
389
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

235
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
235
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

226
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
226
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

269
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
269
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

229
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
229
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

295
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
295

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population pharmacokinetic-based dose adjustment of tiapride in patients with impaired renal function.

Annals of medicine·2026
Same author

Gaps in Glycaemic Monitoring and Underuse of Cardioprotective Glucose-lowering Agents: Challenges of inpatient diabetes care identified by EFIM's Diabesity Day Survey 2024.

European journal of internal medicine·2025
Same author

The Effect of Nutrition Education on Glycemic Outcomes in People With Type 1 Diabetes Initiating the Use of Glucose Sensors.

Endocrinology, diabetes & metabolism·2025
Same author

Treatment of hospitalized patient with hyperglycemia: An EFIM critically appraised and adapted guideline.

European journal of internal medicine·2024
Same author

Glucose variability and diabetic microvascular complications.

Casopis lekaru ceskych·2024
Same author

Glycation in diabetes: is it the same in all patients?

Casopis lekaru ceskych·2024

Related Experiment Video

Updated: Aug 26, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

325

Any expectations from the more powerful dulaglutide?

Jan Škrha

    Vnitrni Lekarstvi
    |October 8, 2022
    PubMed
    Summary

    Dulaglutide, a potent GLP-1 analogue, shows effectiveness in diabetes control and weight management. New data from the AWARD-11 study highlight its benefits at higher concentrations, alongside manageable side effects.

    Area of Science:

    • Endocrinology
    • Pharmacology
    • Metabolic Diseases

    Background:

    • Glucagon-like peptide-1 (GLP-1) analogues are crucial in managing type 2 diabetes.
    • Dulaglutide is a widely prescribed GLP-1 receptor agonist known for its efficacy.
    • Understanding optimal dosing and real-world application is essential for patient outcomes.

    Purpose of the Study:

    • To present practical aspects of dulaglutide treatment.
    • To review new data on higher concentrations of dulaglutide from the AWARD-11 study.
    • To evaluate the effects of dulaglutide on glycemic control, body weight, and safety.

    Main Methods:

    • Review of clinical literature on dulaglutide.
    • Analysis of data from the AWARD-11 study, focusing on higher dulaglutide concentrations.
    Keywords:
    GLP1 receptor agonistsdiabetesdulaglutideheart failurepharmacotherapy

    More Related Videos

    Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
    04:14

    Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

    Published on: April 16, 2019

    12.1K
    Multidisciplinary Approach to Obesity Management: A Case Report
    05:10

    Multidisciplinary Approach to Obesity Management: A Case Report

    Published on: May 30, 2025

    309

    Related Experiment Videos

    Last Updated: Aug 26, 2025

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
    06:34

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

    Published on: November 29, 2024

    325
    Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
    04:14

    Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

    Published on: April 16, 2019

    12.1K
    Multidisciplinary Approach to Obesity Management: A Case Report
    05:10

    Multidisciplinary Approach to Obesity Management: A Case Report

    Published on: May 30, 2025

    309
  • Assessment of efficacy and safety parameters including HbA1c, body weight changes, and adverse events.

    • Main Results:

    • Dulaglutide demonstrates significant improvements in diabetes control (HbA1c reduction).
    • Higher concentrations of dulaglutide are associated with greater body weight reduction.
    • The safety profile remains consistent, with common gastrointestinal side effects.

    Conclusions:

    • Dulaglutide is an effective treatment option for type 2 diabetes, offering benefits in glycemic control and weight management.
    • Higher doses may enhance efficacy, but require careful consideration of side effect profiles.
    • Practical management strategies should be tailored to individual patient needs and responses.